NextPlat (NXPL) Share-based Compensation (2010 - 2026)
NextPlat's (NXPL) quarterly Share-based Compensation came in at $244000.0 in Q2 2026, up 6000.0% year-over-year from $4000.0 in Q2 2025, and down 6.51% quarter-over-quarter from $261000.0 in Q1 2026.
Powered by 
Analysis
NextPlat (NXPL) Share-based Compensation (2010 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Share-based Compensation for 16 consecutive years, with $244000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Share-based Compensation rose 6000.0% year-over-year to $244000.0 in Q2 2026; TTM through Jun 2026 was $1.1 million, a 133.81% increase from a year earlier, with the FY2025 full-year figure at $640000.0, down 60.78% from the prior year.
- Share-based Compensation was $244000.0 for Q2 2026 at NextPlat, down from $261000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.5 million in Q3 2023 and troughed at -$700000.0 in Q2 2022.
- A 5-year average of $618166.7 and a median of $451500.0 in 2024 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation tumbled 227.27% in 2022 and surged 8580.0% in 2025, its largest moves.
- Over 5 years, Share-based Compensation stood at $1.6 million in 2022, then slumped by 50.01% to $815000.0 in 2023, then sank by 100.61% to -$5000.0 in 2024, then surged by 8580.0% to $424000.0 in 2025, then plunged by 42.45% to $244000.0 in 2026.
- The last three Share-based Compensation figures came in at $244000.0 (Q2 2026), $261000.0 (Q1 2026), and $424000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 40.00 Mn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 30.40 Mn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 1.02 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 176,000.00 |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 54.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 11.41 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 2.92 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 29.30 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 7.04 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 244,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 244,000.00 |
| Mar 31, 2026 | 261,000.00 |
| Dec 31, 2025 | 424,000.00 |
| Sep 30, 2025 | 205,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | 479,000.00 |
| Jun 30, 2024 | 546,000.00 |
| Mar 31, 2024 | 612,000.00 |
| Dec 31, 2023 | 815,000.00 |
| Sep 30, 2023 | 2.54 Mn |
| Jun 30, 2023 | 1.78 Mn |
| Mar 31, 2023 | 243,000.00 |
| Dec 31, 2022 | 1.63 Mn |
| Sep 30, 2022 | 643,566.00 |
| Jun 30, 2022 | -700,000.00 |
| Mar 31, 2022 | 1.40 Mn |
| Dec 31, 2021 | 836,804.00 |
| Sep 30, 2021 | 854,892.00 |